rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant.
|
26009876 |
2015 |
rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease.
|
23779130 |
2013 |
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy.
|
18452169 |
2008 |
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
15474988 |
2005 |
rs6624304
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.
|
28176139 |
2017 |
rs6152
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To investigate the relationships between male androgenetic alopecia, androgen receptor (AR) gene polymorphism (SNP rs6152) and clinical characteristics of BPH and prostate cancer.
|
24665929 |
2015 |
rs777787518
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MDA prostate cancer 118a and MDA prostate cancer 118b cells carry a mutated β-catenin at codon 32 (D32G).
|
22298898 |
2012 |
rs139756052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additional studies will be required to define the frequency and contribution of the AR (A1675T) allele to early-onset and/or familial PCa in African Americans.
|
20173765 |
2010 |
rs968098233
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished.
|
15919721 |
2005 |